Sanuwave Health, Inc. SNWV
We take great care to ensure that the data presented and summarized in this overview for SANUWAVE Health, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SNWV
Top Purchases
Top Sells
About SNWV
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.
Insider Transactions at SNWV
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 01
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
16,000
+20.41%
|
$240,000
$15.2 P/Share
|
Oct 31
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
9,868
+25.31%
|
$157,888
$16.29 P/Share
|
Oct 30
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,000
+0.21%
|
$34,000
$17.5 P/Share
|
Oct 18
2024
|
Manchester Management CO LLC |
BUY
Other acquisition or disposition
|
Direct |
29,167
+24.62%
|
$583,340
$20.07 P/Share
|
Oct 18
2024
|
Manchester Management CO LLC |
BUY
Other acquisition or disposition
|
Indirect |
485,622
+9.34%
|
$9,712,440
$20.07 P/Share
|
Oct 18
2024
|
Manchester Management CO LLC |
BUY
Open market or private purchase
|
Indirect |
181,818
+15.3%
|
$1,454,544
$8.25 P/Share
|
Oct 18
2024
|
Manchester Management CO LLC |
BUY
Conversion of derivative security
|
Indirect |
73,790
+3.26%
|
$1,106,850
$15.0 P/Share
|
May 09
2024
|
Manchester Management CO LLC |
BUY
Conversion of derivative security
|
Indirect |
8,625,000
+6.86%
|
$0
$0.04 P/Share
|
Nov 17
2023
|
Manchester Management CO LLC |
BUY
Conversion of derivative security
|
Indirect |
11,500,000
+45.1%
|
$0
$0.04 P/Share
|
Aug 07
2023
|
Manchester Management CO LLC |
BUY
Conversion of derivative security
|
Direct |
10,442,806
+46.65%
|
$0
$0.04 P/Share
|
Aug 07
2023
|
Manchester Management CO LLC |
BUY
Conversion of derivative security
|
Indirect |
71,875,000
+39.86%
|
$0
$0.04 P/Share
|
Last 12 Months Summary
Open market or private purchase | 210K shares |
---|---|
Conversion of derivative security | 20.2M shares |
Other acquisition or disposition | 515K shares |